Research programme: anticancer vaccine - CureTechAlternative Names: CT-201
Latest Information Update: 15 Sep 2011
At a glance
- Originator CureTech
- Class Cancer vaccines
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 03 Aug 2007 Preclinical development is ongoing
- 11 Jun 2005 Preclinical trials in Cancer in Israel (Injection)